A research paper entitled "BCMab1, a monoclonal antibody against aberrantly glycosylated Integrin a3b1, has potent antitumor activity of bladder cancer in vivo" was recently published in the journal Clinical Cancer Research——an authoritative journal of oncology research. A novel tumor marker for bladder cancer abnormal glycosylation of integrin molecule a3b1 was introduced in this paper. This molecule can be used as a brand new bladder cancer tumor markers. The specific antibody BCMab1 and antibody toxin conjugate BCMab1-Ra had significant anti-tumor effect.

  Fan Zusen, who screened a highly specific anti-bladder cancer monoclonal antibody BCMab1, the recognition of the epitope is abnormal glycosylation of integrins modified a3b1. A3b1 was only expressed in the cell membrane of human bladder tumor and was positively correlated with tumor stage and pathological grade of bladder cancer. BCMab1 monoclonal antibody specifically recognizes abnormal glycosylation of integrin a3b1 molecule, which can effectively inhibit the proliferation, migration, adhesion and invasion of tumor cells. The BCMab1 antibody mediated NK cells and macrophages on tumor clearance through the ADCC and ADCP. BCMab1 monoclonal antibody could inhibit the growth of tumor. BCMab1 and BCMab1-Ra could inhibit the growth of tumor. Animals treated with either BCMab1 mAb or BCMab1-Ra did not show systemic or local toxic effects. The study showed that BCMab1 antibody and antibody toxin BCMab1-Ra have a strong ability to inhibit tumor growth. In the future, researchers can use this target to research and develop diagnostic reagents and anti-cancer drug for bladder cancer.

  Bladder cancer is the most common malignant tumor of the urinary system, the incidence rate was classified as the fourth male malignancy in the United States, as the first in China urinary tract tumors. Approximately 95% of bladder cancers are derived from the bladder epithelium, including papilloma, transitional cell carcinoma, squamous cell carcinoma and adenocarcinoma. The vast majority is malignant, of which the most common is transitional cell carcinoma, accounting for more than 80%. Poor prognosis and easy to relapse is the most important feature of bladder cancer, effective treatment will depend on the discovery of specific high-grade bladder cancer tumor markers.

Suzhou Yacoo, reproduced for reference only